In a subsequent clinical protocol with the same CAR-T cells, the authors extended their observations to attenuate the on-target off-tumor cytotoxicity against bile duct epithelial cells, by testing the use of chimeric G250 mAb as a pre-treatment strategy. The gene discussed is CA9; the disease is neoplasm.